Zoetis Falls 60%: Analyst Says Decline Justified, Now Buy

Zoetis shares have fallen 60% from their 2021 highs. The decline erased years of premium valuation built on double-digit revenue growth. Slowing pet adoption after the pandemic and generic competition in parasiticides weighed on the stock.

The company was spun off from Pfizer in 2013. Pfizer stock has also lagged the broader market. Pfizer's Alpha Score is 51, labeled Mixed. Zoetis scores 28, a Weak label.

One Seeking Alpha analyst argues the selloff was justified. Revenue growth decelerated from 15% annual rates to the low single digits. The earnings multiple compressed from above 40x to the mid-20s. The analyst now sees value, citing Zoetis's cash flow, market leadership, and pipeline.

AlphaScala's Alpha Score paints a more cautious picture. The Weak label reflects negative momentum across multiple time frames. The score factors in valuation, momentum, and fundamental trends. Revenue growth has not yet stabilized. Margins remain wide. Generics are beginning to take market share.

The analyst's bullish case rests on new product approvals and pipeline progress. Zoetis has launched biologics for osteoarthritis and dermatology. A ramp in those products could offset losses from parasiticides. The company has also expanded its vaccine portfolio. The analyst holds a long position in Pfizer, not Zoetis, and wrote the article expressing personal opinion.

Industry trends are mixed. Pet adoption rates have normalized after the pandemic surge. Veterinary visit volumes have softened, according to industry data. Pet owners are spending on necessary care but cutting back on discretionary items. Zoetis generates roughly 60% of its revenue in the U.S., making it sensitive to domestic consumer trends.

Competitors have also seen pressure. Idexx shares have fallen 20% from their high. Elanco has declined more sharply. Zoetis's premium valuation was wider than peers, so its compression was deeper. The stock now trades at a discount to its historical average.

Zoetis generates strong free cash flow. It invests in R&D and bolt-on acquisitions. The company also returns capital through dividends and share buybacks. The analyst sees the cash flow as a support for the stock.

The companion animal segment drives the majority of revenue. Livestock products are more stable but offer lower growth. The balance provides some diversification against shifts in pet spending.

For the stock to regain its premium, volume growth would need to accelerate or margins would need to hold. The next quarterly report will test those conditions. A revenue beat or higher guidance would support the buy thesis. A miss would confirm the Weak label.

The Alpha Score has not shown signs of improvement. A move above 40 would be a first signal that headwinds are easing. Until then, the data leans toward caution.

The analyst's view and the Alpha Score represent two different time frames. The analyst looks forward to a recovery. The Alpha Score captures current conditions. Both have merit. The next earnings call will provide the next data point.

Animal health stocks have underperformed the broader market over the past two years. The S&P 500 has climbed while Zoetis has fallen. The divergence reflects sector-specific headwinds, not a broad market selloff.

A U.S. recession would hit pet spending further. Zoetis's revenue would face additional headwinds. The Weak label would persist in that scenario.

For broader market context, see the stock market analysis page. The ZTS stock page and PFE stock page contain full scorecards.